Guess which ASX medical share has exploded 275% in a month?

It's been a brilliant month for this medical technology company.

Key points
  • The 4DMedical share price has more than tripled in a month 
  • The company has developed patented XV technology for detecting ventilation in the lungs 
  • 4DMedical is meeting with US congressmen in a bid to leverage its product in the US market

The S&P/ASX 200 Health Care Index (ASX: XHJ) has climbed 3% in the last month, but this ASX medical share has soared far higher.

The 4DMedical Ltd (ASX: 4DX) share price has rocketed 278% since market close on 3 April from 30 cents to $1.14.

So why has this ASX medical share had such a stellar run lately?

Two scientists in a Rhythm Biosciences lab cheer while looking at results on a computer.

Image source: Getty Images

What's happening?

4DMedical shares have been lifting amid a raft of positive announcements from the company.

In early April, 4DMedical advised it had signed its "first US hospital Software as a Service (SaaS) contract".

Under a five-year contract with the University of Miami, 4DMedical will provide XV technology to enable the processing of patient data. XV technology enables physicians to detect the level of airflow in the lungs. 

4DMedical described the deal as a "significant milestone" for the company's commercialisation strategy in the US.

Then on 13 April, 4DMedical provided further details on this sales contract. Under its terms, a minimum of $1 million to $1.5 million in fees is guaranteed to be paid to the company over a five-year term.

Meanwhile, on 26 April, 4DMedical updated the market with a quarterly report. Receipts from customers grew 67% to $1.2 million in the third quarter. The company reported a cash balance at 31 March of $36.8 million.

The company advised it is continuing to meet with US congress members on Capitol Hill to outline the company's XV Technology and its potential to deliver on PACT Act healthcare for veterans. The former US Secretary for Veterans Affairs, Dr David Shulkin, has recently joined 4DMedical in an advisory role.

Finally, on 1 May, 4DMedical advised it had conducted its first commercial scanning within Veterans Health Administration. This took place at the Harry S. Truman Memorial Veterans Hospital.

Commenting on the news, 4DMedical CEO and founder Andreas Fouras said:

A vision to enable better care for Veterans is core to 4DMedical's mission and culture. I am delighted to share the success of the first commercial scan at Harry S. Truman Memorial Veterans Hospital, completed by our team working alongside VA [Veterans Affairs] medical professionals.

Share price snapshot

The 4DMedical share price has soared 68% in the last year and 170% in the year to date.

This ASX medical share has a market capitalisation of about $334.7 million based on the latest share price.

Motley Fool contributor Monica O'Shea has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Doctor looks at a graph on a tablet.
Healthcare Shares

Ramsay Health Care vs Sonic Healthcare: Which healthcare stock is better value?

Which offers better value — Ramsay Health Care or Sonic Healthcare? I compare their fundamentals, dividends, momentum and reveal my…

Read more »

A doctor looks unsure.
Healthcare Shares

CSL shares jump 93%: Is the ASX biotech stock a buy, sell or hold for October?

Can the CSL share price rebound keep going?

Read more »

Two doctors having a discussion about a patient diagnosis, holding digital tablet.
Healthcare Shares

Are CSL shares a buy after its big news?

I look at what CSL’s latest drug development deal could mean for the healthcare giant’s long-term growth.

Read more »

A female scientist in a laboratory setting using a tablet to review data, with a male scientist working in the background.
Healthcare Shares

ResMed vs Fisher & Paykel Healthcare: Which is better value?

How do ResMed and Fisher & Paykel compare on value, income, and share price momentum? Here’s my verdict on which…

Read more »

Happy doctor using her laptop.
Healthcare Shares

CSL unveils exclusive Alentis deal to advance rare disease treatments

CSL unveils a major partnership for rare disease drug development, enhancing its global nephrology strategy.

Read more »

Doctor sees virtual images of the patient's x-rays on a blue background.
Healthcare Shares

Could this ASX biotech really jump more than 80% in value?

This company's new technology has one broker impressed.

Read more »

Teamwork, planning and meeting with doctors and laptop for medical, review and healthcare. Medicine, technology and internet with group of people for collaboration, diversity and support in hospital
Healthcare Shares

CSL vs Pro Medicus: Which ASX healthcare share is better?

Both CSL and Pro Medicus have faced recent challenges but have enviable long-term track records. Here's which one I'd buy…

Read more »

Scientists working in the laboratory and examining results.
Healthcare Shares

This ASX biotech could rise almost 50%, Morgans says

Turning science into contracts could unlock value for this company.

Read more »